Acceleron Pharma Science & Pipeline

Science & Pipeline

Luspatercept-aamt

Novel erythroid maturation agent in development for treatment of serious and chronic anemias

Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis.

Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.

Hematology

Phase 1Ph1Phase 2Ph2Phase 3Ph3ApprovedApp

Hematology

REBLOZYL®
(luspatercept-aamt)
REBLOZYL® (luspatercept-aamt)
Myelodysplastic Syndromes
Myelodysplastic
Syndromes
Beta-Thalassemia
Beta-Thalassemia
luspatercept-aamt
luspatercept-aamt
Myelodysplastic Syndromes
Myelodysplastic
Syndromes
COMMANDS Trial*COMMANDS Trial*COMMANDS*
Beta-Thalassemia

non-transfusion dependent

Beta-Thalassemia

non-transfusion dependent

BEYOND Trial*BEYOND Trial*BEYOND*
Myelofibrosis
Myelofibrosis
INDEPENDENCE Trial*INDEPENDENCE Trial*INDEP*

* Bristol Myers Squibb-sponsored